Takeda Pharmaceutical TSE 4502 Valuation Check After Positive Zasocitinib Phase 3 Psoriasis Data

2026-03-30 09:48:11

Takeda Pharmaceutical’s recent positive Phase 3 data for zasocitinib in psoriasis has brought its valuation into focus. While analyst consensus suggests the stock is 2.5% overvalued at ¥5,697 with shares trading at ¥5,840, Simply Wall St’s DCF model indicates the stock is significantly undervalued at a fair value of ¥14,743. This discrepancy highlights the importance of understanding the assumptions behind different valuation methods and considering both potential rewards and risks.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.